Intratumoral Fusobacterium as a prognostic and predictive biomarker in resectable colorectal cancer
A study by the FUSOMAP project has identified the presence of Fusobacterium in colorectal tumors as a biomarker for more aggressive cancer subtypes. Patients with this bacteria show a weaker immune response and limited benefit from standard chemotherapy.
Why it matters
This discovery could lead to more personalized cancer treatments, helping clinicians avoid ineffective therapies and better stratify patient risk.
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in